

## **Text S1 - Articles Assessed**

- A1. Chlebowski RT, Col N (2004) Menopausal hormone therapy after breast cancer. *Lancet* 363: 410-411.
- A2. Chlebowski RT, Anderson GL (2005) Progestins and Recurrence in Breast Cancer Survivors. *J Natl Cancer Inst* 97: 471-472.
- A3. Col NF (2006) Decision making at the fringe of evidence: take what you can get. *Arch Intern Med* 166: 389-390.
- A4. Col NF (2005) The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms. *Am J Med* 118 Suppl 12B: 155-162.
- A5. Herrington DM, Howard TD (2003) From presumed benefit to potential harm--hormone therapy and heart disease. *N Engl J Med* 349: 519-521.
- A6. Wenger NK (2004) Diet and exercise for perimenopausal women lifestyle interventions can decrease cardiovascular risk. *J Am Coll Cardiol* 44: 586-587.
- A7. Paoletti R, Wenger NK (2003) Review of the International Position Paper on Women's Health and Menopause: a comprehensive approach. *Circulation* 107: 1336-1339.
- A8. Speroff L (2003) The Million Women Study and breast cancer. *Maturitas* 46: 1-6.
- A9. Speroff L (2004) Postmenopausal hormone therapy and the risk of breast cancer. A clinician's view. *Maturitas* 49: 51-57.
- A10. Speroff L (2005) Clinical appraisal of the Women's Health Initiative. *J Obstet Gynaecol Res* 31: 80-93.
- A11. Kenemans P (2005) Postmenopausal hormone therapy and breast cancer: what is the problem? *Maturitas* 51: 75-82.
- A12. Brood-van Zanten MM, Barentsen R, van der Mooren MJ (2002) Hormone replacement therapy and surveillance considerations. *Maturitas* 43 Suppl 1: S57-67.
- A13. Wenger NK (2005) Menopausal hormone therapy: currently no evidence for cardiac protection. *Pediatr Blood Cancer* 44: 625-629.
- A14. Lobo RA (2005) Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. *Maturitas* 51: 98-109.
- A15. Herrington DM, Klein KP (2003) Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. *Atherosclerosis* 166: 203-212.

- A16. Herrington DM, Parks JS (2004) Estrogen and HDL: all that glitters is not gold. *Arterioscler Thromb Vasc Biol* 24: 1741-1742.
- A17. Kenemans P, Bosman A (2003) Breast cancer and post-menopausal hormone therapy. *Best Pract Res Clin Endocrinol Metab* 17: 123-137.
- A18. van der Mooren MJ, Kenemans P (2003) Postmenopausal hormone replacement therapy in the light of the women's health initiative trial. *Eur J Obstet Gynecol Reprod Biol* 107: 123-124.
- A19. Grimes DA, Lobo RA (2002) Perspectives on the Women's Health Initiative trial of hormone replacement therapy. *Obstet Gynecol* 100: 1344-1353.
- A20. van der Mooren MJ, Kenemans P (2004) Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life. *Drugs* 64: 821-836.
- A21. Clarkson TB, Appt SE (2005) Controversies about HRT--lessons from monkey models. *Maturitas* 51: 64-74.
- A22. Clarkson TB, Appt SE (2003) MPA and postmenopausal coronary artery atherosclerosis revisited. *Steroids* 68: 941-951.
- A23. Mikkola TS, Clarkson TB (2006) Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing? *J Womens Health* 15: 51-53.
- A24. Hickey M, Davis SR, Sturdee DW (2005) Treatment of menopausal symptoms: what shall we do now? *Lancet* 366: 409-421.
- A25. Davison S, Davis SR (2003) Hormone replacement therapy: current controversies. *Clin Endocrinol* 58: 249-261.
- A26. Davis SR, Dinatale I, Rivera-Woll L, Davison S (2005) Postmenopausal hormone therapy: from monkey glands to transdermal patches. *J Endocrinol* 185: 207-222.
- A27. Wagner JD, Clarkson TB (2005) The applicability of hormonal effects on atherosclerosis in animals to heart disease in postmenopausal women. *Semin Reprod Med* 23: 149-156.
- A28. Wenger NK (2003) Coronary heart disease: the female heart is vulnerable. *Prog Cardiovasc Dis* 46: 199-229.
- A29. Speroff L (2005) Postmenopausal hormone therapy and cardiovascular disease: one view of the elephant. *Menopause* 12: 357-358.
- A30. Speroff L (2004) Postmenopausal hormone therapy and breast cancer: a clinician's message for patients. *Endocrine* 24: 211-216.

- A31. Mikkola TS, Clarkson TB, Notelovitz M (2004) Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? *Ann Med* 36: 402-413.
- A32. Herrington DM, Howard TD (2003) ER-alpha variants and the cardiovascular effects of hormone replacement therapy. *Pharmacogenomics* 4: 269-277.
- A33. Lobo RA (2004) The rationale for low-dose hormonal therapy. *Endocrine* 24: 217-221.
- A34. Kenemans P (2005) Women's health after WHI. *Maturitas* 51: 1-3.
- A35. Genazzani AR, Gambaciani M, vand der Mooren MJ, Speroff L, Doren M, et al. (2003) Critical comments. *Maturitas* 44: 11-18.
- A36. Speroff L, Kenemans P, Burger HG (2005) Practical guidelines for postmenopausal hormone therapy. *Maturitas* 51: 4-7.
- A37. van der Mooren MJ, Kenemans P (2004) The Million Women Study: a licence to kill other investigations? *Eur J Obstet Gynecol Reprod Biol* 113: 3-5.
- A38. Clarkson TB, Appt SE, Wood CE, Cline JM (2004) Lessons to be learned from animal studies on hormones and the breast. *Maturitas* 49: 79-89.
- A39. Col NF, Pauker SG (2003) The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? *Ann Intern Med* 139: 923-929.
- A40. Burger H, Archer D, Barlow D, Birkhauser M, Calaf-Alsina J, et al. (2004) Practical recommendations for hormone replacement therapy in the peri- and postmenopause. *Climacteric* 7: 210-216.
- A41. Lobo RA (2004) Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. *Arch Intern Med* 164: 482-484.
- A42. Miller VM, Clarkson TB, Harman SM, Brinton EA, Cedars M, et al. (2005) Women, hormones, and clinical trials: a beginning, not an end. *J Appl Physiol* 99: 381-383.
- A43. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, et al. (2004) The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. *Fertil Steril* 81: 1498-1501.
- A44. Wenger NK (2004) Menopausal hormone therapy: is there evidence for cardiac protection? *Int Urol Nephrol* 36: 617-623.
- A45. Speroff L (2003) WHI trial: it's time to be critical! *Am J Obstet Gynecol* 189: 620.

A46. Klein KP, Herrington DM (2002) Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women. *Medscape Womens Health* 7: 2.

A47. Chlebowski RT, Kim JA, Col NF (2003) Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. *Semin Oncol* 30: 776-788.

A48. Vogelvang TE, van der Mooren MJ, Mijatovic V (2004) Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. *Treat Endocrinol* 3: 105-115.

A49. Wenger NK (2003) Menopausal hormone therapy and cardiovascular protection: state of the data 2003. *J Am Med Womens Assoc* 58: 236-239.

A50. Speroff L (2004) A clinician's review of the WHI-related literature. *Int J Fertil Womens Med* 49: 252-267.